Download PDF
Nervenheilkunde 2020; 39(03): 162-166
DOI: 10.1055/a-1059-1895
Schwerpunkt
© Georg Thieme Verlag KG Stuttgart · New York

Impfungen gegen Infektionskrankheiten bei Multipler Sklerose

Vaccination against infectious diseases in multiple sclerosis
Uwe K. Zettl
1   Sektion für Neuroimmunologie, Zentrum für Nervenheilkunde der Universitätsmedizin Rostock
› Author Affiliations
Further Information

Publication History

Publication Date:
06 March 2020 (online)

    Permissions and Reprints

ZUSAMMENFASSUNG

Einen der größten Erfolge der modernen Medizin stellt die Entwicklung von Impfungen gegen Infektionserkrankungen dar. Dank der Immunisierung sind Ausbrüche von Infektionskrankheiten, die Millionen Menschen das Leben kosten, extrem selten geworden. Bei einer immunvermittelten Erkrankung wie der Multiplen Sklerose und erst recht unter einer immunmodulierenden Therapie (DMT, Disease modifying treatment) sind die Infektionsprophylaxe – und damit auch die Frage des Einsatzes von Impfungen gegen Infektionserkrankungen – von besonderer klinischer Bedeutung.

ABSTRACT

One of the greatest successes of modern medicine is the development of vaccinations against infectious diseases. Thanks to immunization, outbreaks of infectious diseases, costing millions of human lives, have become extremely rare. In immune-mediated diseases such as multiple sclerosis and even more so under immunomodulating therapy (DMT, disease modifying treatment), infection prophylaxis – and thus also the question of using vaccines against infectious diseases – are of clinical importance.

Schlüsselwörter

Infektionsprophylaxe - Impfung - immunmodulierende Therapie - Impfempfehlungen

Key words

Prevention of infections - vaccination - disease modifying treatment - vaccination guidelines
 

  • Literatur

  • 1 McAlpine’s Multiple Sclerosis. Churchill Livingstone 2005
    PubMedGoogle Scholar
  • 2 Smatti MK, Cyprian FS, Nasrallah GK. et al Viruses and Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms. Viruses 2019: 11 doi:10.3390/v11080762
    PubMedGoogle Scholar
  • 3 Cossu D, Yokoyama K, Hattori N. Bacteria-Host Interactions in Multiple Sclerosis. Front Microbiol 2018; 9: 2966
    CrossrefPubMedGoogle Scholar
  • 4 Rivers TM, Schwentker FF. Encephalomyelitis accompanied by myelin destruction experimentally produced in monkeys. J Exp Med 1935; 61: 689-702
    CrossrefPubMedGoogle Scholar
  • 5 Miller H, Cendrowski W, Schapira K. Multiple Sclerosis and Vaccination. BMJ 1967; 2: 210-213
    CrossrefPubMedGoogle Scholar
  • 6 Zrzavy T, Kollaritsch H, Rommer PS. et al Vaccination in Multiple Sclerosis: Friend or Foe?. Front Immunol 2019; 10: 1883
    CrossrefPubMedGoogle Scholar
  • 7 Pacheco Y, Acosta-Ampudia Y, Monsalve DM. et al Bystander activation and autoimmunity. J Autoimmun 2019; 103: 102301
    CrossrefPubMedGoogle Scholar
  • 8 Löbermann M, Handorn B, Winkelmann A. et al Multiple Sklerose und Hepatitis-B-Impfung. Nervenarzt 2018; 10: 1172-1178
    Google Scholar
  • 9 Farez MF, Correale J. Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol 2011; 258: 1197-1206
    CrossrefPubMedGoogle Scholar
  • 10 Hernán MA, Alonos A, Hernandez Diaz S. Tetanus vaccination and risk of multiple sclerosis. Neurology 2006; 67: 212-215
    CrossrefPubMedGoogle Scholar
  • 11 Mailand MT, Frederiksen JL. Vaccines and multiple sclerosis: a systematic review. J Neurol 2017; 264: 1035-1050
    CrossrefPubMedGoogle Scholar
  • 12 Hapfelmeier A, Gasperi C, Donnachie E. et al A large case-control study on vaccination as risk factor for multiple sclerosis. Neurology 2019; 93: e908-e916
    CrossrefPubMedGoogle Scholar
  • 13 De Kayser J, Zwanikken C, Boon M. Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis. J Neurol Sci 1998; 159: 51-53
    CrossrefPubMedGoogle Scholar
  • 14 STIKO Empfehlungen der Ständigen Impfkommission beim Robert-Koch-Institut – 2019/2020. Epidem Bull 2019: 34
    PubMedGoogle Scholar
  • 15 Loebermann M, Winkelmann A, Hartung HP. et al Vaccination against infection in patients with multiple sclerosis. Nat Rev Neurol 2012; 8: 143-151
    CrossrefPubMedGoogle Scholar
  • 16 Winkelmann A, Loebermann M, Reisinger EC. et al Fingolimod treatment for multiple sclerosis patients What do we do with varicella?. Ann Neurol 2011; 70: 673-674
    CrossrefPubMedGoogle Scholar
  • 17 Winkelmann A, Löbermann M, Reisinger EC. et al Therapie der Multiplen Sklerose mit Fingolimod. Infektiologische Aspekte und Hinweise zum Impfverhalten. Nervenarzt 2012; 83: 236-242
    CrossrefPubMedGoogle Scholar
  • 18 Winkelmann A, Loebermann M, Reisinger EC. et al Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol 2016; 12: 217-233
    CrossrefPubMedGoogle Scholar
  • 19 Pellegrino P, Carnovale C, Perrone V. et al Efficacy of vaccination against influenza in patients with multiple sclerosis: The role of concomitant therapies. Vaccine 2014; 32: 4730-4735
    CrossrefPubMedGoogle Scholar
  • 20 Epstein DJ, Dunn J, Deresinski S. Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management. Open Forum Infect Dis 2018; 5: ofy174
    CrossrefPubMedGoogle Scholar
  • 21 Vukusic S, Rollot F, Casey R. et al Progressive multifocal leukoencephalopathy incidence and risk stratification among natalizumab users in France. JAMA Neurol 2019 doi: 10.1001/jamaneurol.2019.2670
    PubMedGoogle Scholar
  • 22 Ryerson LZ, Foley J, Chang I. et al Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology 2019; 93: e1452-e1462
    PubMedGoogle Scholar
  • 23 Siegrist CA. Vaccine Immunology. In: Plotkin’s Vaccines. New York: Elsevier; 2018: 17-36
    Google Scholar
  • 24 Heinemann TC, Cunningham A, Levin M. Understandig the immunology of Shingrix, a recombinant glycoprotein e adjuvanted herpes zoster vaccine. Curr Opin Immunol 2019; 59: 42-48
    CrossrefPubMedGoogle Scholar
  • 25 Rommer PS, Zettl UK. Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients. Expert Opin Pharmacother 2018; 19: 483-498
    CrossrefPubMedGoogle Scholar
  • 26 Kappos L, Mehling M, Arroyo R. et al Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis. Neurology 2015; 84: 872-879
    CrossrefPubMedGoogle Scholar
  • 27 Stokmaier D, Winthrop K, Chognotet C. et al AAN Jahreskongress. 2018. Los Angeles: Abstract S36.002
    Google Scholar
  • 28 Metze C, Winkelmann A, Loebermann M. et al Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies. CNS Neurosci Ther 2019; 25: 245-254
    CrossrefPubMedGoogle Scholar
  • 29 Heesterbeek DAC, Angelier ML, Harrison RA. et al Complement and Bacterial Infections: From Molecular Mechanisms to Therapeutic Applications. J Innate Immun 2018; 10: 455-464
    PubMedGoogle Scholar
  • 30 Alexion. Fachinformation Soliris. Stand August 2019
  • 31 Kennedy PGE, Gershon AA. Clinical Features of Varicella-Zoster Virus Infection. Viruses 2018: 10 doi:10.3390/v10110609
    PubMedGoogle Scholar
  • 32 Winkelmann A, Löbermann M, Zettl UK. Varicella-zoster- und Herpes-zoster-Impfindikation bei Multipler Sklerose: aktuelle Situation. Nervenarzt 2019 doi:10.1007/s00115-019-00806-x
    PubMedGoogle Scholar
  • 33 Caputo M, Horn J, Karch A. et al Herpes zoster incidence in Germany – an indirect validation study for self-reported disease data from pretest studies of the population-based German National Cohort. BMC Infect Dis 2019; 19: 99
    CrossrefPubMedGoogle Scholar
  • 34 Zorzoli E, Pica F, Masetti G. et al Herpes zoster in frail elderly patients: prevalence, impact, management, and preventive strategies. Aging Clin Exp Res 2018; 30: 693-702
    CrossrefPubMedGoogle Scholar
  • 35 Genzyme, Sanofi. Fachinformation Lemtrada® Stand April 2019
  • 36 Merck. Fachinformation Mavenclad® Stand Juli 2018
  • 37 Novartis. Fachinformation Gilenya® Stand Dezember 2018
  • 38 Roche. Fachinformation Ocrevus. Stand Januar 2018
  • 39 MSD. Fachinformation Zostavax® Stand November 2018
  • 40 GSK. Fachinformation Shingrix® Stand April 2019